WALPOLE, Mass.--(BUSINESS WIRE)--Siemens Healthineers largely completed the expansion of its Walpole, Mass. manufacturing and R&D facility and celebrated with a ribbon cutting ceremony today. This milestone means additional, high-tech jobs will soon be available. As of December, the company has created more than 275 positions of its commitment to hire at least 400—meeting 70 percent of its target goal in just over two years. The Walpole facility currently employs more than 900 employees and is the main Siemens Healthineers manufacturing facility for assays that run on the ADVIA® Centaur family of immunoassay instruments, and for consumables for the company’s molecular and blood gas testing instruments. The facility now also manufactures the tests for the immunoassay module of the Atellica® Solution.1 R&D efforts at the site bring new tests to the in-vitro diagnostics market to help physicians diagnose, monitor and treat diseases.
“The $300 million investment Siemens Healthineers is making in the Walpole facility exemplifies the company’s broader strategy for investing in the U.S.—our largest market—and for furthering our ability to innovate transformative healthcare solutions that can improve the lives of the patients served by our products,” said Deepak Nath, Ph.D., President, Laboratory Diagnostics, Siemens Healthineers. “This investment demonstrates the company’s commitment to strong R&D and manufacturing capabilities that deliver robust innovation and an outstanding pipeline of products that are transforming care delivery. The U.S. is an extremely vital production location for Siemens Healthineers, as well as one of the most important research centers, and a key base from which the company exports globally.”
Siemens Healthineers provides more than 10 billion laboratory diagnostic tests globally each year. The Walpole facility is a flagship Siemens Healthineers manufacturing and R&D facility for laboratory diagnostics reagents and devices. Laboratory test results affect 60-70 percent of all critical clinical decisions, such as whether to admit, discharge and/or initiate therapy for a patient.
“Thanks to companies like Siemens Healthineers, Massachusetts continues to be a global leader in the life sciences industry and we are pleased to welcome their growth and investment in Walpole and our Commonwealth to support the global healthcare market,” said Governor Charlie Baker. “We look forward to continuing to partner with Siemens to grow and develop globally competitive life sciences and advanced manufacturing here in Massachusetts.”
1 Product availability varies by country.
Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. In fiscal 2018, which ended on September 30, 2018, Siemens Healthineers generated revenue of €13.4 billion and adjusted profit of €2.3 billion and has about 50,000 employees worldwide. Further information is available at www.siemens-healthineers.com.
